Epidemiology and patient characteristics of the US myasthenia gravis population: real-world evidence from a large insurance claims database
Miller-Wilson L, Arackal J, Edwards Y, Schwinn J, Rockstein K, Venker B, Nowak R. Epidemiology and patient characteristics of the US myasthenia gravis population: real-world evidence from a large insurance claims database. BMJ Neurology Open 2025, 7: e001076. PMID: 40556711, PMCID: PMC12186037, DOI: 10.1136/bmjno-2025-001076.Peer-Reviewed Original ResearchYears of continuous follow-upMyasthenia gravisContinuous insurance coverageContinuous follow-upFollow-upIncident patientsIncident cohortRetrospective claims analysisRare autoimmune diseaseInsurance Claims DatabaseOral steroidsAcetylcholinesterase inhibitorsTreatment paradigmSustained disease controlAutoimmune diseasesEffective therapyMG incidencePatient characteristicsEpidemiology of myasthenia gravisClaims databasePatientsExacerbationCohortMG populationPrevalence rates
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply